相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC
Paul Chauvet et al.
BONE MARROW TRANSPLANTATION (2023)
Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia
David Kegyes et al.
BLOOD REVIEWS (2023)
Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant in patients with ALL
Swati Naik et al.
BLOOD (2022)
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study
Marco Cerrano et al.
HAEMATOLOGICA (2022)
Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia
Mahmoud R. Gaballa et al.
BLOOD (2022)
Pharmacologic Strategies for Post-Transplant Maintenance in Acute Myeloid Leukemia: It Is Time to Consider!
Iman Abou Dalle et al.
CANCERS (2022)
Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment
Firas Kreidieh et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2022)
Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation
Huan Chen et al.
LEUKEMIA RESEARCH (2022)
Changing Landscape in the Treatment of Adult Acute Lymphoblastic Leukemia (ALL)
Tina Kuenz et al.
CANCERS (2022)
The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study
Salvatore Leotta et al.
ANNALS OF HEMATOLOGY (2021)
Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse
Lijuan Ding et al.
FRONTIERS IN ONCOLOGY (2021)
Indications for Allogeneic HCT in Adults with Acute Lymphoblastic Leukemia in First Complete Remission
Shukaib Arslan et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2021)
Therapeutic strategies, including allogeneic stem cell transplantation, to overcome relapsed/refractory adult T-cell acute lymphoblastic leukemia
Dong Won Baek et al.
EXPERT REVIEW OF HEMATOLOGY (2021)
Repetitively Administered Low-Dose Donor Lymphocyte Infusion for Prevention of Relapse after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Leukemia
Panagiotis Tsirigotis et al.
CANCERS (2021)
Maintenance Treatment With Low-Dose Decitabine After Allogeneic Hematopoietic Cell Transplantation in Patients With Adult Acute Lymphoblastic Leukemia
Jia Liu et al.
FRONTIERS IN ONCOLOGY (2021)
Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience
Guillaume Richard-Carpentier et al.
BLOOD ADVANCES (2021)
Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia
Yishai Ofran et al.
LEUKEMIA (2020)
Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival
Shawn Kothari et al.
BONE MARROW TRANSPLANTATION (2020)
Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management
Caitlin R. Rausch et al.
CANCER (2020)
Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia
Tania Jain et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2020)
Evaluation and management of measurable residual disease in acute lymphoblastic leukemia
Iman Abou Dalle et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2020)
Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Ali Bazarbachi et al.
HAEMATOLOGICA (2020)
Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL
Neeraj Saini et al.
BLOOD (2020)
CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia
Jyoti Naik et al.
HAEMATOLOGICA (2019)
Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Iman Abou Dalle et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2019)
Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
Anthony S. Stein et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Ph+ ALL, A Systematic Review
Zabih Warraich et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Inotuzumab Ozogamicin Post-Transplant for Acute Lymphocytic Leukemia
Leland Metheny et al.
BLOOD (2019)
A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia
Yongxian Hu et al.
BONE MARROW TRANSPLANTATION (2019)
Prognosis of relapse after hematopoietic cell transplant (HCT) for treatment of leukemia or myelodysplastic syndrome (MDS) in children
Ann Dahlberg et al.
BONE MARROW TRANSPLANTATION (2019)
Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia
Amy K. Keating et al.
BLOOD ADVANCES (2019)
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia
Karen L. Bride et al.
BLOOD (2018)
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
Nicola Goekbuget et al.
BLOOD (2018)
ASBMT Statement on Routine Prophylaxis for Central Nervous System Recurrence of Acute Lymphoblastic Leukemia following Allogeneic Hematopoietic Cell Transplantation
Craig S. Sauter et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Concomitant Use of Blinatumomab and Donor Lymphocyte Infusion for Post-Transplant Relapsed CD19 Positive Acute Lymphoblastic Leukemia: Systematic Review
Ceren Durer et al.
BLOOD (2018)
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults
Nitin Jain et al.
BLOOD (2017)
Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease
Ghayas C. Issa et al.
CANCER (2017)
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia
Nicola Goekbuget et al.
HAEMATOLOGICA (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia
Nicola Goekbuget et al.
HAEMATOLOGICA (2017)
Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stern Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia
Chen-Hua Yan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Post-Allogeneic Stem Cell Transplantation Maintenance Dasatinib in Philadelphia Chromosome Positive Acute Leukemia
Keri Renee Maher et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD
Elad Jacoby et al.
BLOOD (2016)
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia
Farhad Ravandi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Use of Tyrosine Kinase Inhibitors to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Position Statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Sebastian Gebel et al.
CANCER (2016)
CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients
Cameron J. Turtle et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Phase 1/2 Study of Nilotinib Prophylaxis After Allogeneic Stem Cell Transplantation in Patients With Advanced Chronic Myeloid Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Avichai Shimoni et al.
CANCER (2015)
Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia
Eolia Brissot et al.
HAEMATOLOGICA (2015)
ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia
Sofie Peirs et al.
BLOOD (2014)
Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia
Kheira Beldjord et al.
BLOOD (2014)
The Biology of Relapsed Acute Lymphoblastic Leukemia: Opportunities for Therapeutic Interventions
Teena Bhatla et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2014)
Understanding anti-leukemia responses to donor lymphocyte infusion
Pavan Bachireddy et al.
ONCOIMMUNOLOGY (2014)
Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia
H. Pfeifer et al.
LEUKEMIA (2013)
Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation
Chen-Hua Yan et al.
BLOOD (2012)
Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies
Laura E. Hogan et al.
BLOOD (2011)
Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40
A. W. Rijneveld et al.
LEUKEMIA (2011)
Minimal Residual Disease in Acute Lymphoblastic Leukemia
Dario Campana
HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM (2010)
Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia
Alida Dominietto et al.
BLOOD (2007)
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial
Anthony V. Moorman et al.
BLOOD (2007)
Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study
Deepa Bhojwani et al.
BLOOD (2006)
Responses to donor lymphocyte infusion for acute lymphoblastic leukemia may be determined by both qualitative and quantitative limitations of antileukemic T-cell responses as observed in an animal model for human leukemia
BA Nijmeijer et al.
EXPERIMENTAL HEMATOLOGY (2005)
Donor leukocyte infusions in acute lymphocytic leukemia
RH Collins et al.
BONE MARROW TRANSPLANTATION (2000)